Company Description
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.
Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 13, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Sean Brynjelsen |
Contact Details
Address: 21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7278 United States | |
| Phone | 847 787 7361 |
| Website | etonpharma.com |
Stock Details
| Ticker Symbol | ETON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710340 |
| CUSIP Number | 29772L108 |
| ISIN Number | US29772L1089 |
| Employer ID | 37-1858472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sean E. Brynjelsen | President, Chief Executive Officer and Director |
| James R. Gruber CPA | Chief Financial Officer, Treasurer and Secretary |
| David C. Krempa | Chief Business Officer |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer |
| Danka Radosavljevic | Senior Vice President of Quality and Operations |
| Scott Grossenbach | Senior Vice President of Sales Operations |
| Kevin Guthrie | Executive Vice President of Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 3, 2025 | 144 | Filing |
| May 28, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 2, 2025 | 8-K/A | [Amend] Current report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |